Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22:12:1233-1239.
doi: 10.2147/IJWH.S279426. eCollection 2020.

The Use of Single Dose Methotrexate in the Management of Ectopic Pregnancy and Pregnancy of Unknown Location: 10 Years' Experience in a Tertiary Center

Amer Mahmoud Sindiani  1 , Eman Alshdaifat  2 , Basil Obeidat  1 , Rawan Obeidat  1 , Hasan Rawashdeh  1 , Hashem Yaseen  3
Affiliations

The Use of Single Dose Methotrexate in the Management of Ectopic Pregnancy and Pregnancy of Unknown Location: 10 Years' Experience in a Tertiary Center

Amer Mahmoud Sindiani et al. Int J Womens Health. .

Abstract

Objective: To study factors associated with the success of single dose methotrexate (MTX) treatment in women with ectopic pregnancy.

Methods: This is a retrospective study of women (n=110) with ectopic pregnancy and treated with single dose of MTX. The clinical presentations, transvaginal sonography (TVS) findings, pretreatment beta-human chorionic gonadotropin (β-HCG), and progesterone values were compared between the treatment success (Group S) and treatment failure (Group F) groups.

Results: The overall success rate of treatment with single dose of MTX was 75.45%. The majority of patients in both groups presented with pain and bleeding (~55%), and bleeding only was the presenting symptom in about 20% of patients. Only 3 patients (3.61%) in Group S required a repeat dose of MTX. In contrast, 51.8% of the Group F patients required a repeat dose. The mean pretreatment β-HCG level was 2.3 times higher in Group F than in Group S (1734±1684 vs 4036±2940 IU/L). The data showed a β-HCG level of 3924IU/L as a suitable cut-off value with 76.19% sensitivity and 62.5% specificity to predict MTX treatment success. History of ectopic pregnancy had no relation with success/treatment failure or a repeat dose. None of the TVS findings were related to the outcome of the treatment, whereas pretreatment HCG level was a significant predictor.

Conclusion: The single dose MTX treatment was successful in 75.45% (83/110) of cases, with 3.61% (3/83) requiring a repeat dose of the drug. Pretreatment β-HCG level is a significant predictor of the treatment outcome.

Keywords: ectopic pregnancy; methotrexate; pretreatment β HCG.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
ROC curve for the ability of pretreatment HCG level (IU/L) to predict MTX treatment success.
See this image and copyright information in PMC

References

    1. Marion LL, Meeks GR. Ectopic pregnancy: history, incidence, epidemiology, and risk factors. Clin Obstet Gynecol. 2012;55:376–386. doi:10.1097/GRF.0b013e3182516d7b - DOI - PubMed
    1. Farquhar CM. Ectopic pregnancy. Lancet. 2005;366:583–591. doi:10.1016/S0140-6736(05)67103-6 - DOI - PubMed
    1. Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med. 2009;361:379–387. doi:10.1056/NEJMcp0810384 - DOI - PubMed
    1. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol. 2003;101:778–784. - PubMed
    1. Skubisz MM, Tong S. The evolution of Mtx as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. Obstet Gynecol. 2012;637094. - PMC - PubMed